Should the drug industry work with key opinion leaders? Yes
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39541.702870.59 (Published 19 June 2008) Cite this as: BMJ 2008;336:1404- Charlie Buckwell, chief executive
- 1 Complete Medical Group, Macclesfield, Cheshire SK10 1AQ
- Charlie.Buckwell{at}complete-grp.com
This question is a microcosm of the broader debate about how the drug industry and clinicians should interact. It leads to two tempting but indefensible end points—either that doctors are immune to marketing and should be free to do as they wish with industry or that industry is inherently corrupting, making all contact with it unethical.1
Both positions are flawed, and the reality is much more complex: neither medicine nor industry can realise their true value independently of one another.1 Both have a role in the advancement and delivery of health care. It is not in the interest of the industry to have its products used incorrectly or in the wrong patients, and there are appreciable benefits to healthcare professionals from interactions between industry and opinion leaders.
Current practice
The International Federation of Pharmaceutical Manufacturers and Associations has a clear position on the ethical promotion of prescription medicines. It seeks “to preserve the independence of decisions taken by healthcare …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.